Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
October 22, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of...
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
November 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
June 14, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
June 08, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 16:05 ET
|
Clearside Biomedical, Inc.
- First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase 1/2a Trial - - Management to Host Webcast...
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
May 05, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - - Dr. Thomas Ciulla to Participate in a Panel Discussion at Retina World Congress 2022 on May 12,...
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022 16:05 ET
|
Clearside Biomedical, Inc.
- XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 - -...
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
December 21, 2021 07:05 ET
|
Clearside Biomedical, Inc.
- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to...
Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries
September 09, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 16:05 ET
|
Clearside Biomedical, Inc.
- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October 2021 for XIPERE™ (triamcinolone acetonide...